Ureaplasma urealyticum is a pathogenic bacteria that lacks a cell wall which explains why it is naturally resistant to many common antibiotics especially the beta lactams. Leveraging our wealth of expertise, our firm offers pioneering services for the development of vaccines and therapeutics targeting ureaplasma urealyticum infections.
Overview of Ureaplasma Urealyticum Infection
A member of the Mollicutes class, Ureaplasma urealyticum is a major pathogen, usually in the urogenital area without producing symptoms but capable of causing non-gonococcal urethritis, chorioamnionitis, and even neonatal respiratory diseases. This pathogen is difficult to diagnose, treat and prevent since it is quite small, highly auxotrophic, and has no cell wall.
Fig.1 Bioinformatics analysis of DnaJ based on the amino acid sequences. (Guo F., et al., 2022)
Vaccine Development for Ureaplasma Urealyticum Infection
Recombinant Vaccines
The U. urealyticum vaccine has been worthwhile thanks to the research into the recombinant technology. One such example of a vaccine is DnaJ which has been shown to induce strong both humoral and cellular immune responses in a variety of preclinical animal models. The reason why DnaJ protein, member of the heat shock proteins family, is so highly conserved in the serovars of U. urealyticum species is because it is a very promising target for the development of a broad range vaccine.
Peptide-based Vaccines
Immunogenic proteins from U. urealyticum were used to build a peptide based vaccine utilizing in sillico techniques. These immunogenic peptides, once elicit an immune response are known as immunogenic peptides. This technique has assisted in recognizing greatest non-allergenic, antigenic, and membrane bound proteins as latent vaccine candidates.
Therapeutics Development for Ureaplasma Urealyticum Infection
Azithromycin has often been recommended as an antibiotic due to its effectiveness against Ureaplasma spp. Its usage in the treatment of intra-amniotic infections in pregnancy can be justified owing to its safety profile. On the other hand, doxycycline is another option, but it is not popular in pregnancy due to side effects. These groups of antibiotics have protein synthesis inhibition action and are active against Ureaplasma species. The growing occurrence of resistant strains to fluoroquinolones is also a serious threat – these are indeed active drugs, but new resistant strains develop. Empiric prescription should be informed by continuous monitoring and sensitivity testing.
Our drug development services focus on identifying novel antimicrobial agents with potent activity against U. urealyticum. We also investigate the mechanisms of antibiotic resistance to design drugs that can overcome existing resistance patterns. Please click on the link below to find your one-stop solution.
Our Services
We focus on developing cutting-edge vaccines and therapies for Ureaplasma urealyticum infection which we believe is an outstanding passion for our group. Our company adopts a multidisciplinary approach which ensures integrated rendering of all complex services.
Infectious Disease Models
- Murine Models of Ureaplasma urealyticum Pneumonia
- Newborn Mouse Models (CD-1 outbred mice and C3H/HeN mice)
- Primate Model of Ureaplasma urealyticum Infection in the Premature Infant with Hyaline Membrane Disease
- Novel Mouse Models of Ureaplasma-Induced Perinatal Inflammation
Preclinical research is a critical step in the development of effective vaccines and therapies. Our company offers robust preclinical research services tailored for Ureaplasma urealyticum infection. If you are interested in our services, please feel free to contact us.
References
- Guo, Fangyi, et al. "DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection." Applied Microbiology and Biotechnology 106.22 (2022): 7643-7659.
- Tantengco, Ourlad Alzeus G., and Itaru Yanagihara. "Current understanding and treatment of intra‐amniotic infection with Ureaplasma spp." Journal of Obstetrics and Gynaecology Research 45.9 (2019): 1796-1808.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
